Gilead: A New Cancer Drug! Great…But You Still Overpaid for Kite
October 19, 2017 at 10:22 AM EDT
Gilead Sciences received FDA approval for a new cancer drug, a sign to some that its $12 billion acquisition of Kite Pharma is paying dividends. Yet Leerink analyst Geoffrey Porges still says Gilead overpaid for the deal.
